Skip to main content
construction release_alert
Scholars@Duke will be undergoing maintenance April 11-15. Some features may be unavailable during this time.
cancel

Four year efficacy of prophylactic human papillomavirus quadrivalent vaccine against low grade cervical, vulvar, and vaginal intraepithelial neoplasia and anogenital warts: randomised controlled trial.

Publication ,  Journal Article
FUTURE I/II Study Group, ; Dillner, J; Kjaer, SK; Wheeler, CM; Sigurdsson, K; Iversen, O-E; Hernandez-Avila, M; Perez, G; Brown, DR; Koutsky, LA ...
Published in: BMJ
July 20, 2010

OBJECTIVES: To evaluate the prophylactic efficacy of the human papillomavirus (HPV) quadrivalent vaccine in preventing low grade cervical, vulvar, and vaginal intraepithelial neoplasias and anogenital warts (condyloma acuminata). DESIGN: Data from two international, double blind, placebo controlled, randomised efficacy trials of quadrivalent HPV vaccine (protocol 013 (FUTURE I) and protocol 015 (FUTURE II)). The trials were to be 4 years in length, and the results reported are from final study data of 42 months' follow-up. SETTING: Primary care centres and university or hospital associated health centres in 24 countries and territories around the world. PARTICIPANTS: 17 622 women aged 16-26 years enrolled between December 2001 and May 2003. Major exclusion criteria were lifetime number of sexual partners (>4), history of abnormal cervical smear test results, and pregnancy. INTERVENTION: Three doses of quadrivalent HPV vaccine (for serotypes 6, 11, 16, and 18) or placebo at day 1, month 2, and month 6. MAIN OUTCOME MEASURES: Vaccine efficacy against cervical, vulvar, and vaginal intraepithelial neoplasia grade I and condyloma in a per protocol susceptible population that included subjects who received all three vaccine doses, tested negative for the relevant vaccine HPV types at day 1 and remained negative through month 7, and had no major protocol violations. Intention to treat, generally HPV naive, and unrestricted susceptible populations were also studied. RESULTS: In the per protocol susceptible population, vaccine efficacy against lesions related to the HPV types in the vaccine was 96% for cervical intraepithelial neoplasia grade I (95% confidence interval 91% to 98%), 100% for both vulvar and vaginal intraepithelial neoplasia grade I (95% CIs 74% to 100%, 64% to 100% respectively), and 99% for condyloma (96% to 100%). Vaccine efficacy against any lesion (regardless of HPV type) in the generally naive population was 30% (17% to 41%), 75% (22% to 94%), and 48% (10% to 71%) for cervical, vulvar, and vaginal intraepithelial neoplasia grade I, respectively, and 83% (74% to 89%) for condyloma. CONCLUSIONS: Quadrivalent HPV vaccine provided sustained protection against low grade lesions attributable to vaccine HPV types (6, 11, 16, and 18) and a substantial reduction in the burden of these diseases through 42 months of follow-up. TRIAL REGISTRATIONS: NCT00092521 and NCT00092534.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

BMJ

DOI

EISSN

1756-1833

Publication Date

July 20, 2010

Volume

341

Start / End Page

c3493

Location

England

Related Subject Headings

  • Young Adult
  • Vulvar Neoplasms
  • Vaginal Neoplasms
  • Uterine Cervical Neoplasms
  • Uterine Cervical Dysplasia
  • Urogenital Neoplasms
  • Treatment Outcome
  • Papillomavirus Vaccines
  • Papillomavirus Infections
  • Humans
 

Citation

APA
Chicago
ICMJE
MLA
NLM
FUTURE I/II Study Group, ., Dillner, J., Kjaer, S. K., Wheeler, C. M., Sigurdsson, K., Iversen, O.-E., … Haupt, R. (2010). Four year efficacy of prophylactic human papillomavirus quadrivalent vaccine against low grade cervical, vulvar, and vaginal intraepithelial neoplasia and anogenital warts: randomised controlled trial. BMJ, 341, c3493. https://doi.org/10.1136/bmj.c3493
FUTURE I/II Study Group, Richard, Joakim Dillner, Susanne K. Kjaer, Cosette M. Wheeler, Kristján Sigurdsson, Ole-Erik Iversen, Mauricio Hernandez-Avila, et al. “Four year efficacy of prophylactic human papillomavirus quadrivalent vaccine against low grade cervical, vulvar, and vaginal intraepithelial neoplasia and anogenital warts: randomised controlled trial.BMJ 341 (July 20, 2010): c3493. https://doi.org/10.1136/bmj.c3493.
FUTURE I/II Study Group, Dillner J, Kjaer SK, Wheeler CM, Sigurdsson K, Iversen O-E, Hernandez-Avila M, Perez G, Brown DR, Koutsky LA, Tay EH, García P, Ault KA, Garland SM, Leodolter S, Olsson S-E, Tang GWK, Ferris DG, Paavonen J, Lehtinen M, Steben M, Bosch FX, Joura EA, Majewski S, Muñoz N, Myers ER, Villa LL, Taddeo FJ, Roberts C, Tadesse A, Bryan JT, Maansson R, Lu S, Vuocolo S, Hesley TM, Barr E, Haupt R. Four year efficacy of prophylactic human papillomavirus quadrivalent vaccine against low grade cervical, vulvar, and vaginal intraepithelial neoplasia and anogenital warts: randomised controlled trial. BMJ. 2010 Jul 20;341:c3493.

Published In

BMJ

DOI

EISSN

1756-1833

Publication Date

July 20, 2010

Volume

341

Start / End Page

c3493

Location

England

Related Subject Headings

  • Young Adult
  • Vulvar Neoplasms
  • Vaginal Neoplasms
  • Uterine Cervical Neoplasms
  • Uterine Cervical Dysplasia
  • Urogenital Neoplasms
  • Treatment Outcome
  • Papillomavirus Vaccines
  • Papillomavirus Infections
  • Humans